Evidence map›Paper›PMID 35294181›Full record

ArticleACS chemical biology2022

Chemical Labeling and Enrichment of Histone Glyoxal Adducts.

Devin M Ray, Erin Q Jennings, Igor Maksimovic, Xander Chai, James J Galligan, Yael David, Qingfei Zheng

Abstract read
In one paragraph

Article in ACS chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Biocompatible Chemistry: A Plug-and-Play Toolbox for Chemical Biology Research.Chembiochem : a European journal of chemical biology · 2025
    Review
  4. Article
  5. Identification of Methylglyoxal Reactive Proteins with Photocaged Glycating Agents.Chembiochem : a European journal of chemical biology · 2025
    Article
  6. Review
  7. The chemical language of protein glycation.Nature chemical biology · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Chemical proteomics approaches for protein post-translational modification studies.Biochimica et biophysica acta. Proteins and proteomics · 2024
    Review
  12. Article
  13. Epigenetic meets metabolism: novel vulnerabilities to fight cancer.Cell communication and signaling : CCS · 2023
    Review
  14. Review
  15. Review
  16. eLife · 2023
    Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Devin M RayTri-Institutional MD-PhD Program, New York, New York 10065, United States.ORCID 0000-0003-4557-7930
Erin Q JenningsDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
Igor MaksimovicTri-Institutional PhD Program in Chemical Biology, New York, New York 10065, United States.ORCID 0000-0002-4379-6884
Xander ChaiDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
James J GalliganDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.ORCID 0000-0002-5612-0680
Yael DavidTri-Institutional PhD Program in Chemical Biology, New York, New York 10065, United States.ORCID 0000-0003-1696-0025

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Translating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DALLA-FAVERA, RICCARDO, ZELENETZ, ANDREW D. · 2016 to 2020
$10.9M
Training in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7M
Investigating histone glycation as a new dynamic epigenetic markR35GM138386 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID-SHTERNBERG, YAEL E · 2020 to 2024
$2.2M
Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease [Equipment Supplement]R35GM137910 · NIGMS · UNIVERSITY OF ARIZONA · PI GALLIGAN, JAMES J · 2020 to 2024
$2.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NIEHS NIH HHS T32 ES007091NIGMS NIH HHS R35 GM137910NIGMS NIH HHS R35 GM138386NIGMS NIH HHS T32 GM007739
6 · The paper itself

Abstract

Because of their long half-lives and highly nucleophilic tails, histones are particularly susceptible to accumulating nonenzymatic covalent modifications, such as glycation. The resulting modifications can have profound effects on cellular physiology due to the regulatory role histones play in all DNA-templated processes; however, the complexity of Maillard chemistry on proteins makes tracking and enriching for glycated proteins a challenging task. Here, we characterize glyoxal (GO) modifications on histones using quantitative proteomics and an aniline-derived GO-reactive probe. In addition, we leverage this chemistry to demonstrate that the glycation regulatory proteins DJ-1 and GLO1 reduce levels of histone GO adducts. Finally, we employ a two-round pull-down method to enrich histone H3 GO glycation and map these adducts to specific chromatin regions.

Indexed as

GlyoxalHistonesChromatinGlycosylationProteomicsChromatinGlyoxalHistones

Identifiers

PMID35294181
PMCPMC9124041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.